We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > APN01

News List

APEIRON Biologics’ APN01 Selected for US COVID-19 Trail americanpharmaceuticalreview
May 20, 2021
APEIRON Biologics, a private European biotech company, announced next steps for APN01 (alunacedase alfa) for COVID-19 treatment.
Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial pharmaceutical-technology
April 06, 2020
Apeiron Biologics has secured approvals from regulatory agencies in Austria, Germany and Denmark to conduct a Phase II clinical trial of APN01 for the treatment of Covid-19.
APEIRON Biologics Initiates Phase II COVID-19 Trial contractpharma
April 03, 2020
APN01 has potential to block infection of cells by COVID-19 virus and reduce lung injury.